Skip to main content
SpringerLink
Log in

Solide Tumoren

  • Chapter
Medizinische Therapie 2007 | 2008

  • 139 Accesses

Auszug

Das Mammakarzinom ist der häufigste bösartige Tumor der Frau in unseren Breiten. In Mitteleuropa und Nordamerika ist ca. jede zehnte Frau im Laufe ihres Lebens davon betroffen; es stellt die häufigste Todesursache von Frauen im Alter zwischen 35 und 45 Jahren dar. Der Altersgipfel für Brustkrebs liegt in der 7. Lebensdekade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 39.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Baum, M, AU Budzar, J Cuzick et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131–2139.

    PubMed  CAS  Google Scholar 

  • Fisher ER, Land SR, Fisher B et al. (2004) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelveyear observations concerning lobular carcinoma in situ. Cancer 100:238–244

    PubMed  Google Scholar 

  • Goldhirsch A, et al.: Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 16 (2005) 1569–83

    PubMed  CAS  Google Scholar 

  • Howell A, JF Robertson, P Abram, et al.: Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22 (2004) 1605–1613.

    PubMed  CAS  Google Scholar 

  • Kennedy MJ, Abeloff MD (1993) Management of locally recurrent breast cancer. Cancer 71:2395–2409

    PubMed  CAS  Google Scholar 

  • Mouridsen H, Gershanovich M, Sun Y et al. (2003) Phase III study of letrozole versus tamoxifen as firstline therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101–2109

    PubMed  CAS  Google Scholar 

  • NIH, National Institutes of Health (2000) Consensus Development Conference Statement — adjuvant therapy for breast cancer.

    Google Scholar 

  • Piccart-Gebhart MJ, et al.: Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl. J Med 353 (2005) 1659–72

    PubMed  CAS  Google Scholar 

  • Romond EH, et al: Trastuzumab plus Adjuvant Chemotherapy for operable HER2-Positive Breast Cancer. N Engl. J Med 353 (2005) 1673–84

    PubMed  CAS  Google Scholar 

  • Silverstein MJ, Buchanan C (2003) Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast 12:457–471

    PubMed  Google Scholar 

  • Singletary SE, Allred C, Ashley P et al. (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628–3636

    PubMed  Google Scholar 

  • Slamon DJ, B Leyland-Jones, S Shak et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792.

    PubMed  CAS  Google Scholar 

Literatur

  • Bolla M. et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial. Lancet 266:572–578, 2005

    Google Scholar 

  • Calais Da Silva F. et al. Phase III study of intermittent mab versus continuous mab. Uur Urol Suppl 5(2): 1066, 2006

    Google Scholar 

  • Fachgesellschaften Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften. S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms) http//:www.awmf-online.de, 2002

    Google Scholar 

  • Hu J.C. et al. Perioperative quality care indicators of retropubic, laparoscopic and robotic prostatectomy: results from a national, multi center, prospective cohort. J Urol 175(4): 1151, 2006

    Google Scholar 

  • Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostat ecancer. J Urol 172(5 Pt 2):48–50, 2004

    Google Scholar 

  • Messing E. et al. J Urol 169(4): 396, 2003

    Google Scholar 

  • Patchell T. et al. Lancet (366): 396, 2003

    Google Scholar 

  • Petrylak D.P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351:1513–1520, 2004

    PubMed  CAS  Google Scholar 

  • Pollack A. et al. Int J Radiat. Oncol Biol Phys 53(5): 1097–1105, 2002

    PubMed  Google Scholar 

  • Stone N.N. et al. I-125 Brachytherapy of Prostate Cancer Among 514 Men with High-Grade Prostatic Intraepithelial Neoplasia (PIN): Results of a Double-Blind, Pöacebo-Controlled Phase IIB Trial. J Urol 173(4), 2005

    Google Scholar 

  • Studer U.E. et al. Immediate versus Deferred Androgen Deprivation in Patients with Asymptomatic Prostate Cancer T0-4 N0–2 M0 Not Suitable for Local Definitive Treatment. J Urol 173(4), 2005

    Google Scholar 

  • Studer U.E. et al. Patients with prostate cancer not suitable for local treatment with curative intent (EORTC30891): Which subgroup needs or does not need immediate treatment? J Urol 175(4): 1592, 2006

    Google Scholar 

  • Tannock I.F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512, 2004

    PubMed  CAS  Google Scholar 

  • Thompson I.M. et al. N Engl J Med 349:215–224, 2003

    PubMed  CAS  Google Scholar 

  • Thompson I.M. et al. Adjuvant Radiotherapy for Pathologic T3 Prostate Cancer: Results of a Randomized, Prospective Trial with Metastasis-Free Survival Endpoint. J Urol 173(4), 2005

    Google Scholar 

  • Thueroff S., Chaussy C. Prostale cancer treatmenl costs: what influences them? Eur Urol Suppl 5(2):1036, 2006

    Google Scholar 

  • Tombai B. et al. Immediate extcrnal beam radiation therapy after radical prostatectomy: long term influence on QOL, urinary and rectal Symptoms J. rol. 175(4): 1599, 2006

    Google Scholar 

  • Wirth M. et al. Adjuvant therapy with bicalutamide 150mg versus Standard care alone Eur Urol Suppl 5(2):913, 2006

    Google Scholar 

Literatur

  • Weißbach L, Albers P (2001) Hodentumoren. In: Rübben H (Hrsg) Uroonkologie, 3. Aufl. Springer, Berlin Heidelberg New York Tokio, S 361–467

    Google Scholar 

  • Krege S, Schmoll H-J, Souchon R (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidenz-basierter Medizin (EBM). Urol A 40:137–147

    CAS  Google Scholar 

  • Schmoll HJ, Souchon R, Krege S (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Annals of Oncology 15:1377–1399

    PubMed  CAS  Google Scholar 

  • (EGCCCG) Annals of Oncology 15:1377–1399

    Google Scholar 

Literatur

  • Castilla LH, Couch SJ, Erdos MR et al. (1994) Mutations in the BRCA1-Gene in families with earlyonset breast and ovarian cancer. Mature Genet 8:387–391

    CAS  Google Scholar 

  • Deutsche Krebsgesellschaft (1998/2000/2001) Qualitätssicherung in der Onkologie. Diagnose und Therapie maligner Erkrankungen. Kurzgefasste Interdisziplinäre Leitlinien 2000, S 301 ff

    Google Scholar 

  • Emons G, Ortmann O, Pahwa GS (1992) LH-RH agonists in the treatment of ovarian cancer. In: Höffken K (ed) Peptides in oncology I. LH-RH agonists and antagonists. Zuckschwerdt, München Bern Wien New York, p 55

    Google Scholar 

  • Grab D, Flock F, Stöhr I (2000) Classification or asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 77: 454–459

    PubMed  CAS  Google Scholar 

  • Kuhn W (2001) Maligne Ovarialtumoren, 6. Aufl. W. Zuckschwerdt, München, S 24–31

    Google Scholar 

  • Kuhn W, Rutke S, Späthe K et al. (2001) Neoadjuvant chemotherapy followed by tumordebulking prolongs survival for patients with poor prognosis in ovarian cancer FIGO III c. Cancer: in press

    Google Scholar 

  • Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Secondline platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393

    PubMed  CAS  Google Scholar 

  • National Cancer Institute (1998) Screening for ovarian cancer. Tumorzentrum München

    Google Scholar 

  • Rutke S, Späthe K, Schmalfeldt B, Graeff H, Kuhn W (2000) Primäre Chemotherapie beim fortgeschrittenen Ovarialkarzinom: Alternative zum radikalen operativen Tumordebulking? In: Schmid L, Wilmanns (eds) Praktische Onkologie. Akt Onkol Bd 109, Zuckschwerdt, München Bern Wien New York, pp 141–147

    Google Scholar 

  • Schelling, Kuhn, Gnirs et al. (1998) Kombination von Sonographie und farbkodierter Dopplersonographie zur Dignitätsbeurteilung von Ovarialtumoren. Geburtsh Frauenheilk 58: 382–387

    Google Scholar 

  • Scully RE, Sobin LH (1999) World Health Organisation (WHO). International histological classification of tumours. Histological typing of ovarian tumours. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Scully RE, Young RH, Clement Ph B (1998) Atlas of tumor pathology: Tumors of ovary, maldeveloped gonads, fallopian tube, and broad ligament. AFIP, Washington, D.C.

    Google Scholar 

  • Sobin LH, Wittekind C (1997) UICC, TNM Classification of malignant tumors, 5. Aufl. Wiley-Liss, New York

    Google Scholar 

  • Uzolds RS, Rubin SC, Thomas G, Robbuy S (1997) Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 2nd edn. Lippencott Raven, Philadelphia, p 919

    Google Scholar 

Literatur

  • ACOG, Commitee Opinion (1993) Estrogen replacement therapy and endometrial cancer. p 126

    Google Scholar 

  • Alberts DS, Mason-Liddil N (1989) The role of cisplatin in the management of advanced squamous cell cancer of the cervix. Semin Oncol 16(Suppl 6): 66–78

    PubMed  CAS  Google Scholar 

  • Atzinger A (1996) Bestrahlung beim Zervixkarzinom nach radikaler Operation: Welches Zielvolumen? Ist prophylaktische Bestrahlung der Paraaortalregion effektiv? Strahlenther Onkol 172:229–230

    PubMed  CAS  Google Scholar 

  • AWMF online (2001) Therapie der Adipositas. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Leitlinien der Deutschen Adipositas-Gesellschaft

    Google Scholar 

  • Barakat RR, Park RC, Grigsby PW, Muss HD, Norris HJ (1997) Corpus: epithelial tumors. In: Hoskins et al. (eds) Principles and practice of gynecologic oncology. Lippincott Williams & Wilkins, Philadelphia, pp 859 ff

    Google Scholar 

  • Berman ML, Ballon SC, Lagasse LD, Watring WG (1980) Prognosis and treatment of endometrial cancer. Am J Obstet Gynecol 136: 679–688

    PubMed  CAS  Google Scholar 

  • Bischoff J (2000) Hormon-und Chemotherapie in der Rezidivund Palliativsituation. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 52–56

    Google Scholar 

  • Buckley SL, Tritz DM, Van Le L et al. (1996) Lymph node metastases and prognosis in patients with stage IA2 cervical cancer. Gynec Oncol 63:4–9

    CAS  Google Scholar 

  • Burghardt E, Girardi F, Lahousen M et al. (1991) Microinvasive carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics Stage OA). Cancer 67:1037

    PubMed  CAS  Google Scholar 

  • Burghardt E, Östör A, Fox H (1997) Editorial: The new FIGO definition of cervical cancer stage I a: a critique. Gynecol Oncol 65:1–5

    PubMed  CAS  Google Scholar 

  • Burghardt E, Webb MJ, Monaghan JM, Kindermann G (1993) Surgical gynecologic oncology. Thieme, Stuttgart New York

    Google Scholar 

  • Creasman WT (1995) New gynecologic cancer staging. Gynec Oncol 58:157–158

    CAS  Google Scholar 

  • Delgado G, Bundy BN, Fowler WE et al. (1989) A prospective surgical pathological study of stage I squamous carcinoma of cervix: a Gynecologic Oncology Group study. Gynecol Oncol 35:314

    PubMed  CAS  Google Scholar 

  • Deutsche Krebsgesellschaft (2000) B22 Endometriumkarzinom. In: Qualitätssicherung in der Onkologie — Diagnose und Therapie maligner Erkrankungen. Kurzgefasste interdiszi-plinäre Leitlinien 2000. Zuckschwerdt, München, S 287 ff

    Google Scholar 

  • DiSaia PJ, Creasman WT (1997) Sarcoma of the uterus. In: Clinical gynecologic oncology, 5th ed. Mosby, St. Louis Baltimore Boston, pp 169–179

    Google Scholar 

  • Geisthövel F (1998) Obesity in female life — from molecular to clinical aspects. Zentralbl Gynakol 120(5): 223–234

    PubMed  Google Scholar 

  • Gershenson DM, Kavanagh JJ, Copeland LJ, Edwards CL, Stringer CA, Wharton JT (1987) Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 5(4): 618–621

    PubMed  CAS  Google Scholar 

  • Glassburn JR (1981) Carcinoma of the endometrium. Cancer 48: 575–581

    PubMed  CAS  Google Scholar 

  • Gusberg SB (1976) The evolution of modern treatment of corpus cancer. Cancer 38:603–609

    PubMed  CAS  Google Scholar 

  • Hatch KD, Gelder MS, Soong SJ, Baker VV, Shingleton HM (1990) Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol 38: 462–467

    PubMed  CAS  Google Scholar 

  • Hoffmann W, Hirnle P, Clemens M et al. (1995) 13cisretinoic acid in combination with interferonalpha and concomitant irradiation in squamous cell carcinomas — toxicity and feasibility. Onkologie 18:568–571

    Article  Google Scholar 

  • Hoffmann W, Schiebe M, Clemens M, Souchon R, Hirnle P, Adamietz I, Bambert M (1997) 13cisretinoic acid and interferonalpha ± irradiation in squamous cell carcinomas. Int J Cancer 70:475–477

    PubMed  CAS  Google Scholar 

  • IARC Monograph (1995) IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. IARC, Lyon, p 64

    Google Scholar 

  • Käser O (1983) Operative Möglichkeiten bei der Therapie des Endometriumkarzinoms. Gynäkologe 16:99–103

    PubMed  Google Scholar 

  • Kreienberg R (1998) Fortgeschrittene Stadien des invasiven Zervixkarzinoms — Operative Therapie. Onkologe 2:142–152

    Google Scholar 

  • Kumar L, Grover R, Pokharel YH, Chander S, Kumar S, Singh R, Rath GK, Kochupillai V (1998) Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies. Aust N Z J Med 28:387–390

    PubMed  CAS  Google Scholar 

  • Lacava JA, Leone BA, Machiavelli M et al. (1997) Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 15:604–609

    PubMed  CAS  Google Scholar 

  • Larson B, Silfverswärd C, Nilsson B, Petterson F (1990) Mixed Müllerian tumours of the uterus — prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 17:123–132

    PubMed  CAS  Google Scholar 

  • Lawton F (1997) The management of endometrial cancer. Br J Obstet Gynaecol 104:127–134

    PubMed  CAS  Google Scholar 

  • Leminen A, Forss M, Lehtovirta P (1995) Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand 74:61–66

    PubMed  CAS  Google Scholar 

  • Limper A, Rauthe G (2000) Nachsorge. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 57–69

    Google Scholar 

  • Lindner H, Likas P, Willgeroth F, Würschmidt F (2000) Radioonkologische Behandlung. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 39–46

    Google Scholar 

  • Lippman SM, Kavanagh JJ, Paredes-Espinoza M et al. (1992) 13-cisretinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241–245

    PubMed  CAS  Google Scholar 

  • Lotocki RJ, Copeland LJ, De Petrillo AD, Muirhead W (1983) Stage I endometrial carcinoma: treatment results in 835 patients. Am J Obstet Gynecol 146:141–145

    PubMed  CAS  Google Scholar 

  • Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL (1993) Prognostic factors in early stage uterine sarcoma — a GOG study. Cancer 71:1702–1706

    PubMed  CAS  Google Scholar 

  • Manchul L, Pintilie M, Lefebvre P, Fyles A, Kirkbride P, Levin W, Rawlings G (1994) Uterine sarcomas: prognostic factors and the role of radiation therapy. Int J Radiat Oncol Biol Phys 30(SuppM):284

    Google Scholar 

  • Möbus V, Kreienberg R (1998) Systemische Therapie des Zervixkarzinoms. Onkologe 4:167–173

    Google Scholar 

  • Morris M, Eifel PJ, Lu J et al. (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for highrisk cervical cancer. N Engl J Med 340: 1137–43

    PubMed  CAS  Google Scholar 

  • National Cancer Institute (1999) Concurrent chemoradiation for cervical cancer. Clinical announcement, Washington, D.C.

    Google Scholar 

  • Oberlechner E (2000) Adjuvante medikamentöse Therapie. In: Tumorzentrum München: Manual Malignome des Corpus uteri. Zuckschwerdt, München, S 47–51

    Google Scholar 

  • Park RC, Thigpen JT (1993) Chemotherapy in advanced and recurrent cervical cancer. A review. Cancer 71(Suppl): 1446–1450

    CAS  Google Scholar 

  • Pecorelli S (1998) FIGO Annual report on the results of treatment in gynaecological cancer, 23rd ed. J Epidemiol Biostat 3:1–168

    Google Scholar 

  • Peters III WA, Liu PY, Barrett II RJ et al. (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvanttherapy after radical surgery in highrisk earlystage cancer of the cervix. J Clin Oncol 18:1606–1613

    PubMed  CAS  Google Scholar 

  • Pettersson F (1994) Annual report on the results of treatment in gynecological cancer. Radiumhemmet, Stockholm

    Google Scholar 

  • Potter ME, Hatch KD, Potter MY, Shingleton HM, Baker VV (1989) Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 63:1283–1286

    PubMed  CAS  Google Scholar 

  • Rakar S, Kovacic J (1990) Prognostic factors in endometrial cancer. Eur J Gynaec Oncol 11:233–235

    CAS  Google Scholar 

  • Sardi J, Sananes C, Giaroli AR et al. (1993) Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 49:156–165

    PubMed  CAS  Google Scholar 

  • Scully RE, Bonfiglio T, Kurman RJ, Silverberg S, Williamson EJ (1994) World Health Organization international histological classification of tumors, histological typing of female genital tract tumors, 2nd ed. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Shingleton HM, Thompson JD (1997) Cancer of the cervix. In: Rock JA, Thompson JD (eds) Te Linde’s operative gynecology. Lippincott-Raven, Philadelphia New York, pp 1413–1499

    Google Scholar 

  • Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Cancer 73:1453–1455

    PubMed  CAS  Google Scholar 

  • Thomas GM (1999) Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. Editorial. N Engl J Med 340:1198–1200

    PubMed  CAS  Google Scholar 

  • Thomas GM (2000) Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care. Semin Radiat Oncol 10(1): 44–50

    PubMed  CAS  Google Scholar 

  • Toki N, Tsukamoto N, Kaku T, Toh N, Saito T, Kamura T, Matsukuma K, Nakano H (1991) Microscopic ovarian metastasis of the uterine cervical cancer. Gynecol Oncol 41:46–51

    PubMed  CAS  Google Scholar 

  • Wulf J, Flentje M (1998) Strahlentherapie des Zervixkarzinoms. Onkologe 4:153–166

    Google Scholar 

Literatur

  • Albeida SM (1998) Gene therapy for lung cancer and mesothelioma. Chest 111:144S–149S

    Google Scholar 

  • Antman KH, Pass HI, Schiff PB (2001) Management of Mesothelioma. In: De Vita VT Jr (ed) Cancer. Principles and Practice of Oncology, 6th edn. Section 2. Lippincott, Williams and Wilkins, Philadelphia, pp 1943–1964

    Google Scholar 

  • Baas P, Murrer L, Zoetmulder FA et al. (1997) Photodynamic therapy as adjuvant therapy in surgically resected pleural malignancies. Br J Cancer 76:819–826

    PubMed  CAS  Google Scholar 

  • Byrne MJ, Davidson JA, Musk AW et al. (1999) Cisplatin and Gemcitabine treatment for malignant mesothelioma. A phase-II study. J Clin Oncol 17:25

    PubMed  CAS  Google Scholar 

  • Chahinian GA, Pass HI (2000) Malignant mesothelioma. In: Bast RC, Kufe DW, Pollock RE et al. (eds) Cancer Medicine, 5th edn. B.C. Decker, News York, pp 1293–1312

    Google Scholar 

  • Eberhardt W, Dienemann H, Stüben G (2002) Malignes Mesotheliom. In: Seeber S, Schütte J (eds) Therapiekonzepte Onkologie. Springer, Berlin Heidelberg New York Tokyo (im Druck)

    Google Scholar 

  • Giaccone G, Baas P (1999) Mesotheliomas. In: Raghavan D, Brecher ML, Johnson DH et al. (eds) Textbook of uncommon cancer, 2nd edition, pp 523–535. Wiley, Chichester New York Weinheim Brisbane Singapore Toronto

    Google Scholar 

  • Peto J, Decarli A, La Vecchia C et al. (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672

    PubMed  CAS  Google Scholar 

  • Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 108:1122

    PubMed  CAS  Google Scholar 

  • Sugarbaker DJ, Garcia JP, Richards et al. 1996) Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surgery 224:288

    CAS  Google Scholar 

  • Testa JR, Pass HI, Carbone M (2001) Molecular biology of mesothelioma. In: De Vita (ed) Cancer. Principles and Practice of Oncology. 6th edition. Section 2. Lippincott, Williams and Wilkins, Philadelphia, pp 1937–1942

    Google Scholar 

  • Van Meerbeeck J, Manegold C, R. Gaafar, et al. (2004) A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An inter-group study of the EORTC Lung Cancer Group and NCIC. J Clin Oncol 22 (July 15 Supplement): 7021

    Google Scholar 

  • Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644

    PubMed  CAS  Google Scholar 

  • Weder W, Kestenholz P, Taverna C, et al. (2004) Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22:3451–3457

    PubMed  CAS  Google Scholar 

Literatur

  • Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P (2000) Highdose chemotherapy with autologous hematopoietic stemcell transplantation for advanced softtissue sarcoma in adults. J Clin Oncol 3643–3650

    Google Scholar 

  • Coindre JM, Terrier P, Binh Bui N, Bonichon F, Collin F, Le Doussal V et al. (1996) Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14:869–877

    PubMed  CAS  Google Scholar 

  • Graadt van Roggen JF, van Velthuysen MLF, Hogendoorn PCW (2001) The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 54: 96–103

    PubMed  CAS  Google Scholar 

  • Guillou L, Coindre JM, Bonichon F, Binh Bui N, Terrier P, Collin F, et al. (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group Grading Systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350–362

    PubMed  CAS  Google Scholar 

  • Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES et al. (1997) Prognostic factors associated with longterm survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 15:2832–2839

    PubMed  CAS  Google Scholar 

  • Issels R, Abdel-Rahman S, Wendtner CM, Falk MH, Kurze V, Sauer H et al. (2001) Neoadjuvant chemotherapy combined with regional hyperthermie (RHT) for locally advanced primary or recurrent highrisk adult softtissue sarcomas (STS) of adults: longterm results of a phase II study. Eur J Cancer 37:1599–1608

    PubMed  CAS  Google Scholar 

  • Issels R (2004) Empfehlungen zur Diagnostik, Therapie und Nachsorge. Knochentumoren/Weichteilsarkome, 4. Aufl. Tumorzentrum München (Hrsg.) W. Zuckerschwerdt Verlag München

    Google Scholar 

  • Koscielniak E, Harms D, Henze G, Jürgens H, Gadner H, Herbst M et al. (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Group CWS-86. J Clin Oncol 17:3706–3719

    PubMed  CAS  Google Scholar 

  • Trovik CS, Bauer HCF, Alvegard TA, Anderson H, Blomqvist C, Berlin Ö et al. (2000) Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgicallytreated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 36:710–716

    PubMed  CAS  Google Scholar 

  • Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH et al. (2002) Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts longterm survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 20:3156–3164

    PubMed  CAS  Google Scholar 

  • Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL et al. (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16:197–203

    PubMed  CAS  Google Scholar 

Literatur

  • Ang KK, Trotti A, Brown BW et al. (2001) Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced headandneck cancer. Int J Radiat Oncol Biol Phys 51:571–578

    PubMed  CAS  Google Scholar 

  • Awwad HK, Lotayef M, Shouman T et al. (2002) Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cander 86:517–523

    CAS  Google Scholar 

  • Bernier J, Domenge C, Ozsahin M et al. (2004) Postoperative irridiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350: 1945–1952

    PubMed  CAS  Google Scholar 

  • Browman GP, Hodson DI, Mackenzie RJ et al. (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for sqamous cell head and neck cancer: a systematic review of the published literature with a subgroup analysis. Head Neck 23:579–589

    PubMed  CAS  Google Scholar 

  • Budach V, Budach W (2001) Sequentielle und simultane Radiochemotherapie bei lokal fortgeschrittenen Kopf-Hals-Tumoren. Onkologe 5:533–549

    Google Scholar 

  • Cooper JS, Pajak TF, Forastiere AA et al. (2004) Postoperative concurrent radiotherapy and chemotherapy in highrisk squamouscell carcinoma of the head and neck. N Engl J Med 350:1937–1944

    PubMed  Google Scholar 

  • El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A metaanalysis of prospective and randomized trials. J Clin Oncol 14:838–847

    PubMed  CAS  Google Scholar 

  • Ganly I, Kaye SB (2000) Recurrent squamouscell carcinoma of the head and neck: overview of current and future prospects. Ann Oncol 11:11–26

    PubMed  CAS  Google Scholar 

  • Jacobs C, Lyman G, Velez-Garcia E (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257–263

    PubMed  CAS  Google Scholar 

  • List MA, Haraf D, Stracks J, Stenson B, Brockstein M, Kies F, Rosen E, Vokes EE (2000) Quality of life (QOL) performance in head and neck cancer (HNC): comparison between paclitaxelbased (P-CT/XRT) and cisplatinbased (C-CT/XRT) concomitant chemoradiotherapy regimens. Proc Am Soc Clin Oncol 19:412a(A1625)

    Google Scholar 

  • Pignon JP, Bourhis J, Domenge C et al. (2000) Chemotherapy added to local treatment for head and neck squamous cell carcinoma: three metaanalyses of updated individual data. MACH-NC collaborative group. Lancet 355:949–955

    PubMed  CAS  Google Scholar 

  • Posner MR, Colevas D (2000) The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Sem Oncol 27:13–24

    CAS  Google Scholar 

  • Vokes EE, Athanasiadis I (1996) Chemotherapy for squamous cell carcinoma of head and neck: the future is now. Ann Oncol 7:15–29

    PubMed  CAS  Google Scholar 

  • Wendt TG, Grabenhauer GG, Rödel CM (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16:1318–1324

    PubMed  CAS  Google Scholar 

  • Wust P, Stahl H, Dieckmann K (1996) Local hyperthermia of N2/N3 cervical lymph node metastases: correlation of technical/thermal parameters and response. Int J Radiat Oncol Biol Phys 34(3): 635–646

    PubMed  CAS  Google Scholar 

Literatur

  • Bokemeyer C (1999) Tumormetastasen bei unbekanntem Primärtumor. In: Thiemes Innere Medizin. Thieme, Stuttgart New York, S 1022–1027

    Google Scholar 

  • Bugat R, Bataillard A, Lesimple T et al. (2002) Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 89:59–66

    Google Scholar 

  • Culine S, Kramar A, Saghatchian M et al. (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 24:4679–4683

    Google Scholar 

  • Culine S, Lortholary A, Voigt JJ et al. (2003) Cisplatin in compination with either gemcitabine of Irinotecan in carcinomas of unknown primary site: results of a randomized phase II study — trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol 18:3479–3482

    Google Scholar 

  • Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras J (2003) Metaanalysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44:1301–1314

    PubMed  Google Scholar 

  • Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA (1997) Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extendedschedule etoposide. J Clin Oncol 15:2385–2393

    PubMed  CAS  Google Scholar 

  • Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403–3410

    PubMed  CAS  Google Scholar 

  • Hübner G, Wildfang I, Schmoll HJ (1999) Metastasen bei unbekanntem Primärtumor — CUP-Syndrom. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie, 3. Aufl. Springer, Berlin Heidelberg New York Tokyo, S 2137–2182

    Google Scholar 

  • Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005

    PubMed  CAS  Google Scholar 

  • Van de Wouw AJ, Jansen RL, Speel EJM, Hillen HFP (2003) The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 14:191–196

    PubMed  Google Scholar 

  • Varadhachary GR, Abbruzzese JL, Lenzi R (2004) Diagnostic strategies for unknown primary cancer. Cancer 100:1776–1785

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik II mit Schwerpunkt Onkologie, Hämatologie, Charité — Campus Mitte, Charitéplatz 1, 10117, Berlin

    Prof. Dr. Kurt Possinger & Dr. Anne C. Regierer

  2. Klinik und Poliklinik für Urologie, Kinderurologie, Urologische Onkologie, Universitätsklinik Essen, Hufelandstraße 55, 45122, Essen

    Dr. Christof Börgermann & Dr. Frank vom Dorp

  3. Urologische Klinik, Städtische Kliniken Neuss Lukaskrankenhaus, Preußenstraße 84, 41464, Neuss

    Prof. Dr. Thomas Otto & Prof. Dr. Herbert Rübben

  4. Klinik und Poliklinik für Urologie, Kinderurologie, Urologische Onkologie, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen

    PD Dr. Susanne Krege & Prof. Dr. Herbert Rübben

  5. Frauenklinik mit Nathanstift, Klinikum Fürth, Jacob-Henle-Straße 1, 90766, Fürth

    Prof. Dr. Volker Hanf

  6. Universitätsfrauenklinik und Poliklinik, Universitätsklinikum Ulm, Prittwitzstraße 43, 89075, Ulm

    Prof. Dr. Rolf Kreienberg

  7. Frauenklinik mit Nathanstift, Klinikum Fürth, Jacob-Henle-Straße 1, 90766, Fürth

    Prof. Dr. Volker Hanf

  8. Universitätsfrauenklinik und Poliklinik, Universitätsklinikum Ulm, Prittwitzstraße 43, 89075, Ulm

    Prof. Dr. Rolf Kreienberg

  9. Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen

    Dr. Wilfried Eberhardt

  10. Medizinische Klinik und Poliklinik III, Klinikum der Universitäts München — Großhadern und GSF — Forschungszentrum für Umwelt und Gesundheit, Marchioninistraße, 81377, München

    Prof. Dr. Rolf D. Issels

  11. Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité — Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin

    Prof. Dr. Hanno Riess

  12. Klinik für Onkologie, Hämatologie und Knochenmarktransplantation Zentrum Innere Medizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. Carsten Bokemeyer

  13. Hämatologie und Onkologie mit der Sektion Pneumologie II. Medizinische Klinik Zentrum für Innere Medizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg

    Dr. Jan Wierecky

Authors
  1. Prof. Dr. Kurt Possinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Anne C. Regierer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Christof Börgermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. Frank vom Dorp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. Thomas Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr. Herbert Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. PD Dr. Susanne Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Prof. Dr. Herbert Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Prof. Dr. Volker Hanf
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Prof. Dr. Rolf Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Prof. Dr. Volker Hanf
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Prof. Dr. Rolf Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Dr. Wilfried Eberhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Prof. Dr. Rolf D. Issels
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Prof. Dr. Hanno Riess
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Prof. Dr. Carsten Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Dr. Jan Wierecky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg, 93042, Regensburg

    Jürgen Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Possinger, K. et al. (2007). Solide Tumoren. In: Schölmerich, J. (eds) Medizinische Therapie 2007 | 2008. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-48554-4_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-48554-4_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-48553-7

  • Online ISBN: 978-3-540-48554-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation